↓ Skip to main content

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

Overview of attention for article published in Cardiovascular Diabetology, October 2020
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
62 Mendeley